Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. reports developments in hemp-derived cannabinoid consumer products, including the cbdMD, Paw CBD, Bluebird Botanicals and Herbal Oasis brands.
Company news focuses on CBD product categories, THC-infused social seltzer distribution, clinical and regulatory science initiatives, acquisitions, financial results, liquidity, balance-sheet actions and exchange-listing compliance.
cbdMD (NYSE American: YCBD) reported fiscal 2025 results for the year ended September 30, 2025, citing its third consecutive year of operating improvement and steps to strengthen the balance sheet and regain exchange compliance.
Key facts: Net sales $19.19M, gross margin 62%, loss from operations $2.16M (improved vs $3.32M in 2024), net loss to common $4.38M, cash $2.26M, and shareholders' equity ≈ $7.23M. Financing actions include $1.7M Series B (closed Sept 2025), $2.25M Series C (closed Dec 18, 2025), and a $20M equity line of credit (Dec 15, 2025 amendment).
The company said it resolved NYSE American listing deficiencies and noted an audit explanatory paragraph regarding its ability to continue as a going concern.
cbdMD (NYSE American: YCBD) reported fiscal 2025 results for the year ended September 30, 2025, citing its third consecutive year of operating improvement and steps to strengthen the balance sheet and regain exchange compliance.
Key facts: Net sales $19.19M, gross margin 62%, loss from operations $2.16M (improved vs $3.32M in 2024), net loss to common $4.38M, cash $2.26M, and shareholders' equity ≈ $7.23M. Financing actions include $1.7M Series B (closed Sept 2025), $2.25M Series C (closed Dec 18, 2025), and a $20M equity line of credit (Dec 15, 2025 amendment).
The company said it resolved NYSE American listing deficiencies and noted an audit explanatory paragraph regarding its ability to continue as a going concern.
cbdMD (NYSE American: YCBD) announced on December 19, 2025 the closing of a private placement of 1,000,000 shares of Series C convertible preferred stock for gross proceeds of $2.25 million.
The company expects net proceeds of approximately $2.1 million to be used for working capital, general corporate purposes, and to support strategic initiatives, including expanding distribution of its consumer brands.
The Series C carries a 10% annual dividend and is convertible at the holder's option into common stock at an initial conversion price of $2.25 per share, with anti-dilution protection and rights substantially the same as the company’s Series B preferred.
cbdMD (NYSE American: YCBD) announced on December 19, 2025 the closing of a private placement of 1,000,000 shares of Series C convertible preferred stock for gross proceeds of $2.25 million.
The company expects net proceeds of approximately $2.1 million to be used for working capital, general corporate purposes, and to support strategic initiatives, including expanding distribution of its consumer brands.
The Series C carries a 10% annual dividend and is convertible at the holder's option into common stock at an initial conversion price of $2.25 per share, with anti-dilution protection and rights substantially the same as the company’s Series B preferred.
cbdMD (NYSE American: YCBD) will host a conference call on Friday, December 19, 2025 at 4:20 p.m. ET to discuss its September 30, 2025 fourth quarter and fiscal year 2025 financial results and business progress.
Investors in the USA/Canada can join by phone at 888-880-3330. A live webcast and replay are available via the provided link and will remain accessible through December 19, 2026.
cbdMD (NYSE American: YCBD) will host a conference call on Friday, December 19, 2025 at 4:20 p.m. ET to discuss its September 30, 2025 fourth quarter and fiscal year 2025 financial results and business progress.
Investors in the USA/Canada can join by phone at 888-880-3330. A live webcast and replay are available via the provided link and will remain accessible through December 19, 2026.
cbdMD (NYSE American: YCBD) announced it has regained full compliance with NYSE American listing standards and that the “.BC” noncompliance indicator was removed effective at the open of trading on December 8, 2025. The NYSE American notified the company on December 5, 2025 that cbdMD resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
Management highlighted the May Series A Preferred share conversion and a capital raise completed in September as key elements of the company’s compliance plan. cbdMD said it will remain subject to NYSE American continued listing monitoring procedures and will file a Form 8-K with the SEC on December 8, 2025 for additional details.
cbdMD (NYSE American: YCBD) announced it has regained full compliance with NYSE American listing standards and that the “.BC” noncompliance indicator was removed effective at the open of trading on December 8, 2025. The NYSE American notified the company on December 5, 2025 that cbdMD resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
Management highlighted the May Series A Preferred share conversion and a capital raise completed in September as key elements of the company’s compliance plan. cbdMD said it will remain subject to NYSE American continued listing monitoring procedures and will file a Form 8-K with the SEC on December 8, 2025 for additional details.
cbdMD (NYSE American: YCBD) reported preliminary unaudited results for the fourth quarter and fiscal year ended September 30, 2025. Fiscal 2025 net sales are expected to be between $19.1M and $19.3M versus $19.5M in fiscal 2024, and Q4 net sales are expected to be $4.7M–$4.9M vs $4.6M in Q4 2024 (a 3%–5% increase).
Fiscal 2025 net loss is expected to improve to $1.9M–$2.1M from a $3.7M loss in 2024. Management attributes improvement to cost discipline and operating changes and plans a mid-December earnings call to discuss results.
cbdMD (NYSE American: YCBD) reported preliminary unaudited results for the fourth quarter and fiscal year ended September 30, 2025. Fiscal 2025 net sales are expected to be between $19.1M and $19.3M versus $19.5M in fiscal 2024, and Q4 net sales are expected to be $4.7M–$4.9M vs $4.6M in Q4 2024 (a 3%–5% increase).
Fiscal 2025 net loss is expected to improve to $1.9M–$2.1M from a $3.7M loss in 2024. Management attributes improvement to cost discipline and operating changes and plans a mid-December earnings call to discuss results.